Related Experiment Video

Updated: May 16, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Cardiovascular risk and dyslipidemia management in HIV-infected patients

James H Stein1

  • 1Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA.

Topics in Antiviral Medicine
|November 17, 2012
PubMed

Insights

HIV infection and antiretroviral therapy may increase cardiovascular disease risk, particularly for those with existing coronary heart disease (CHD) risk factors. Further research is needed to confirm the long-term impact on cardiovascular health.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • HIV infection and its treatment with antiretroviral therapy (ART) are associated with increased cardiovascular disease (CVD) risk.
  • Inflammation from HIV and dyslipidemia from ART contribute to this elevated risk.
  • CVD prevalence is rising in aging HIV-positive populations with traditional coronary heart disease (CHD) risk factors.

Purpose of the Study:

  • To summarize current understanding of CVD risk in HIV-infected patients.
  • To discuss the impact of HIV and ART on cardiovascular health.
  • To outline management strategies for dyslipidemia and CHD risk in this population.

Main Methods:

  • Review of existing literature and clinical observations regarding HIV, ART, and CVD.
  • Summary of a presentation on cardiovascular risk in HIV-infected individuals.
  • Discussion of risk factors and management principles.

Main Results:

  • Both HIV infection and ART appear to elevate CVD risk.
  • Patients with existing CHD risk factors are of particular concern.
  • Long-term studies are required to fully quantify the cardiovascular risks associated with HIV and ART.

Conclusions:

  • Management of dyslipidemia in HIV-infected patients mirrors general population guidelines, emphasizing statins and lifestyle changes.
  • Smoking cessation is crucial for reducing CHD risk.
  • Continued research is essential to clarify the long-term cardiovascular implications of HIV and its treatment.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...